BECTON, DICKINSON AND COMPANY Becton, Dickinson and Company Stock
Equities
BDX
US0758871091
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 231.6 USD | +0.46% |
|
-1.10% | -5.04% |
| 04-26 | Becton, Dickinson and Company acquired FlowJo LLC. | CI |
| 04-05 | Becton Dickinson Releases New Image-Enabled Cell Sorters | MT |
| Sales 2024 * | 20.31B 27.76B | Sales 2025 * | 21.5B 29.39B | Capitalization | 66.9B 91.44B |
|---|---|---|---|---|---|
| Net income 2024 * | 2.1B 2.88B | Net income 2025 * | 2.54B 3.48B | EV / Sales 2024 * | 3.93 x |
| Net Debt 2024 * | 12.83B 17.54B | Net Debt 2025 * | 10.55B 14.43B | EV / Sales 2025 * | 3.6 x |
| P/E ratio 2024 * |
33.8
x | P/E ratio 2025 * |
28.2
x | Employees | 73,000 |
| Yield 2024 * |
1.61% | Yield 2025 * |
1.64% | Free-Float | 77.71% |
More Fundamentals
* Assessed data
More news
Latest transcript on Becton, Dickinson and Company
More recommendations
More press releases
| 1 day | +0.46% | ||
| 1 week | -1.10% | ||
| Current month | -6.43% | ||
| 1 month | -4.27% | ||
| 3 months | -2.16% | ||
| 6 months | -8.90% | ||
| Current year | -5.04% |
1 week
230.00
236.18
1 month
229.40248.42
Current year
229.40249.89
1 year
229.40287.32
3 years
215.90287.32
5 years
197.75287.32
10 years
111.07287.32
| Managers | Title | Age | Since |
|---|---|---|---|
Thomas Polen
CEO | Chief Executive Officer | 50 | 08-12-31 |
| Director of Finance/CFO | 52 | 21-09-05 | |
| Chief Tech/Sci/R&D Officer | 48 | 18-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Bertram Scott
BRD | Director/Board Member | 73 | 02-09-23 |
Catherine Burzik
BRD | Director/Board Member | 73 | 13-01-28 |
| Director/Board Member | 69 | 10-07-25 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 15.40% | 215 M€ | +10.68% | - | |
| 2.47% | 6 M€ | +16.84% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 231.6 | +0.46% | 738,154 |
| 24-04-25 | 230.5 | -1.43% | 885,117 |
| 24-04-24 | 233.8 | -0.23% | 779,855 |
| 24-04-23 | 234.4 | +0.21% | 800,508 |
| 24-04-22 | 233.9 | -0.10% | 768,416 |
Delayed Quote Nyse, April 26, 2024 at 04:00 pm
More quotes
Becton, Dickinson and Company specializes in the development, manufacturing and marketing of medical and diagnostic equipment and materials. Net sales break down by family of products as follows:
- medical equipment (73.5%): surgical instruments, urological care products, pharmaceutical systems, etc.;
- diagnostic materials (18.7%): automated systems for blood testing, mycobacteria detection, and molecular biology, medical biology devices, etc.;
- clinical research and development tools (7.8%): tools for discovering drugs and vaccines, studying genes, culturing cells, and manipulating liquids, instruments for sorting and analyzing cells, monoclonal antibodies, etc.
Net sales are distributed geographically as follows: the United States (57.4%), Europe/Middle East/Africa (21.9%), Asia (15%) and other (5.7%).
Calendar
2024-05-02
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A
Sell
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
231.6
USD
Average target price
279
USD
Spread / Average Target
+20.48%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -5.04% | 66.9B | |
| -2.31% | 187B | |
| -3.20% | 106B | |
| +0.20% | 49.45B | |
| +17.29% | 48B | |
| +4.06% | 40.84B | |
| +2.07% | 26.48B | |
| +2.36% | 26.25B | |
| +12.96% | 24.62B | |
| -1.93% | 24.52B |
- Stock Market
- Equities
- BDX Stock
